IBA has acquired PhantomX GmbH, a German company specializing in AI quality assurance tools for diagnostic and therapeutic imaging systems.

The move expands IBA’s dosimetry capabilities, integrating AI validation capabilities into its existing quality assurance solutions.

Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz with support from Charité University Hospital in Berlin, PhantomX develops advanced phantoms used by hospitals and research institutions globally. The company’s technology supports validation of AI applications in imaging workflows, with a focus on safety and performance assurance.
“PhantomX’s expertise in AI validation perfectly complements IBA’s portfolio of Clinical Workflow Solutions in Radiation Therapy and Medical Imaging,” said Jean-Marc Bothy, president of IBA Dosimetry. “Together, we will accelerate innovation in our Medical Imaging Business Line with simulation and AI-driven technologies, delivering greater value to clinicians and patients worldwide.”

Commenting on the acquisition, Dr. Jahnke said, “This merger empowers us to bring our technology to new markets and contribute to the future of intelligent, safe, and effective medical solutions.”

PhantomX’s offerings are expected to support IBA’s expansion into AI-enhanced imaging QA, a growing area of focus as hospitals and developers seek tools to independently validate machine learning algorithms used in diagnostics.

Financial terms of the transaction were not disclosed.

Business Affairs Homepage